Results 61 to 70 of about 662,207 (147)

Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of anti-diabetic agents [PDF]

, 2014
Although several treatment options are available to reduce hyperglycemia, only about half of individuals with diagnosed diabetes mellitus (DM) achieve recommended glycemic targets.
Eva M Vivian
core   +1 more source

Impact of Sodium–Glucose Cotransporter 2 Inhibitors on Acute Kidney Injury Post Off-Pump Coronary Artery Bypass Grafting: A Retrospective Cohort Study and Meta-Analysis

Reviews in Cardiovascular Medicine
Background: Sodium–glucose cotransporter 2 (SGLT2) inhibitors, a novel class of oral antihyperglycemic medications prescribed for type 2 diabetes mellitus, play a beneficial role in slowing the progression of heart failure.
Xiaozheng Zhou, Yilin Pan, Kun Hua, Xiubin Yang   +3 more
doaj   +1 more source

SGLT2 Inhibitors in MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) Associated with Sustained Hepatic Benefits, Besides the Cardiometabolic

Pharmaceuticals
Background and Aims: Sodium-glucose cotransporter-2 (SGLT2) inhibitors have shown promise in metabolic dysfunction-associated steatotic liver disease (MASLD). This large real-world study aimed to evaluate the effects of SGLT2 inhibitors on MASLD patients’
Mohamad Suki, Ashraf Imam, Johnny Amer, Yael Milgrom, Muhammad Massarwa, Wadi Hazou, Yariv Tiram, Ofer Perzon, Yousra Sharif, Joseph Sackran, Revital Alon, Nachum Lourie, Anat Hershko Klement, Safa Shibli, Tamer Safadi, Itamar Raz, Abed Khalaileh, Rifaat Safadi   +17 more
doaj   +1 more source

Prevalence Rate of Adverse Drug Reactions from Sodium-Glucose Cotransporter-2 Inhibitors: A Retrospective Cohort Study

Pharmacoepidemiology
Background/Objectives: Sodium-glucose cotransporter-2 (SGLT2) inhibitors are widely used in type 2 diabetes mellitus for glycemic control and cardiovascular–renal protection, but adverse effects such as acute kidney injury (AKI), urinary tract infection (
Pichitra Srimaya, Tossapol Warong, Sudarat Kingdang, Titawadee Pradubkham, Wiraphol Phimarn   +4 more
doaj   +1 more source

The effect of SGLT2 inhibitor in patients with type 2 diabetes and atrial fibrillation.

BackgroundSodium glucose cotransporter 2 (SGLT2) inhibitors improve clinical outcomes in several populations including type 2 diabetes (T2D), chronic renal insufficiency, and heart failure (HF).
Young Ju Suh, Dae-Young Kim, Sung-Hee Shin, Min-Ae Park, Ji-Hun Jang, So Hun Kim, Yongin Cho, Sojeong Park   +7 more
core   +1 more source

Research Progress of SGLT2 Inhibitors in Cancer Treatment [PDF]

Xiaoyong Miao,1,* Jianing Zhang,2,* Weiyan Huang,2,* Yifei Wang,1 Aixia Jin,1 Jianping Cao,1 Zhenzhen Zhao3 1Department of Anesthesiology, Naval Medical Center, Naval Medical University, Shanghai, People’s Republic of China; 2Student Brigade,
Jin A, Zhang J, Huang W, Cao J, Miao X, Wang Y, Zhao Z   +6 more
core  

SGLT2 Inhibitor Use and Bioprosthetic Valve Re-Intervention in Patients with Diabetes

IntroductionStructural valve degeneration (SVD) remains a major limitation of bioprosthetic heart valves (BHVs), particularly among patients with diabetes mellitus, in whom inflammation, oxidative stress, and advanced glycation accelerate valve ...
Kaylyn Lunneborg, Kristen Sell-Dottin, Ramzi Ibrahim, Michael Killian, Reza Arsanjani, Kamal Awad, Joy Plutowski, Juan Maria Farina, Chadi Ayoub, Said Alsidawi, Hoang Nhat Pham, Mohammed Tiseer Abbas, Steven J. Lester   +12 more
core   +1 more source

The Impact of SGLT2 Inhibitors on Hemoglobin Levels in Type 2 Diabetes: Potential Benefits Beyond Glycemic and Renal Outcomes [PDF]

Aim: Sodium-glucose cotransporter 2 (SGLT2) inhibitors are antidiabetic agents with proven cardiovascular and renal benefits. Recent evidence suggests they may also increase hemoglobin (Hb) levels through mechanisms beyond hemoconcentration.
Nilsu Kalayci, Emre Hoca
core   +1 more source

Differential Cardiometabolic Effects of GLP-1 Receptor Agonists Versus SGLT2 Inhibitors in Early-Onset Type 2 Diabetes: A Randomized Controlled Trial

Link Medical Journal of Health and Community Research
Introduction: Early-onset type 2 diabetes mellitus is characterized by higher exposure to cardiometabolic risk throughout life and increased risk of cardiovascular morbidity.
Marriam Abid, Samia Gull Akhtar, Tabinda Razzaq, Zia Ullah, Shah Abdul Latif, Hafiz Muhammad Qasim, Muhammad Abbas Sadiq   +6 more
doaj   +1 more source

SGLT2 inhibitors prevent long-COVID-associated cognitive and pain symptoms in type 2 diabetes patients

Virology Journal
Background Long COVID presents significant health challenges, especially for patients with type 2 diabetes. Emerging evidence suggests that sodium-glucose cotransporter-2 (SGLT2) inhibitors may provide protective effects against COVID-19 complications ...
Han-Wei Yeh, Chung-Hsien Chaou, Shun-Fa Yang, Yu-Hsun Wang, Yu-Hsiang Kuan, Chao-Bin Yeh   +5 more
doaj   +1 more source